Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3088050 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL3091944 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL16398820 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL27576037 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL30893366 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL3090350 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL3103903 | 1.00 | TSHR (0.73) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL28240769 | 0.98 | TSHR (0.70) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL28331125 | 0.98 | TSHR (0.70) | TSHRALDH1A1ABCC4MAPTPPARA | |
| Sulfuric Acid SCHEMBL18107891 | 0.98 | TSHR (0.70) | TSHRALDH1A1ABCC4MAPTPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | claimed |
| US-20100285601-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-11-11 | — | — | US | claimed |
| WO-2009041917-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-04-02 | — | — | WO | claimed |
| US-20080038772-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20080038773-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-9763978-B2 | Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150064131-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE | VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) | 2015-03-05 | — | — | US | disclosed |
| US-8883133-B2 | Pharmaceutical compositions comprising polymeric binders with non-hydrolysable their use in treating celiac disease | VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) | 2014-11-11 | — | — | US | disclosed |
| US-8784792-B2 | Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease | Valorization-Recherche Limited Partnership (CA) | 2014-07-22 | — | — | US | disclosed |
| US-20120244105-A1 | Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease | VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20100285601-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-11-11 | — | — | US | disclosed |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | GENZYME CORPORATION (US) | 2006-02-09 | — | — | US | disclosed |
| US-6890523-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | GELTEX PHARMACEUTICALS, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6517827-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6517826-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1189622-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | Geltex Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6290946-B1 | ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000069428-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | DDOST, DNPEP, IDUA | TSHR 821/4885ALDH1A1 1727/4885ABCC4 2156/4885 |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | MSN, ANTXR2, PNKP | TSHR 1345/4885ALDH1A1 4470/4885ABCC4 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.